Branding/Logomark minus Citation Combined Shape Icon/Bookmark-empty Icon/Copy Icon/Collection Icon/Close Copy 7 no author result Created with Sketch. Icon/Back Created with Sketch. Match!
Heiko Schuster
University of Tübingen
48Publications
13H-index
508Citations
Publications 48
Newest
Published on Apr 30, 2019in Genome Medicine 10.89
Markus Loeffler77
Estimated H-index: 77
,
Christopher Mohr4
Estimated H-index: 4
+ 28 AuthorsLena Mühlenbruch
Although mutated HLA ligands are considered ideal cancer-specific immunotherapy targets, evidence for their presentation is lacking in hepatocellular carcinomas (HCCs). Employing a unique multi-omics approach comprising a neoepitope identification pipeline, we assessed exome-derived mutations naturally presented as HLA class I ligands in HCCs. In-depth multi-omics analyses included whole exome and transcriptome sequencing to define individual patient-specific search spaces of neoepitope candidat...
Published on May 16, 2019in Journal of Proteome Research 3.78
J. Patrick Murphy9
Estimated H-index: 9
,
Youra Kim6
Estimated H-index: 6
+ 8 AuthorsSteven P. Gygi139
Estimated H-index: 139
Oncolytic viruses (OVs), known for their cancer-killing characteristics, overturn tumor-associated defects in antigen presentation through the MHC class I pathway and induce protective neo antitumor CD8 T cell responses. Nonetheless, whether OVs shape the tumor MHC-I ligandome remains unknown. Here, we investigated if an OV induces the presentation of novel MHC I-bound tumor antigens (termed tumor MHC-I ligands). Using comparative mass spectrometry (MS)-based MHC-I ligandomics, we determined dif...
Published on Apr 16, 2019in Analytical Chemistry 6.35
J. Patrick Murphy9
Estimated H-index: 9
(Dal: Dalhousie University),
Qijia Yu (Harvard University)+ 11 AuthorsAditya Jain (Harvard University)
MHC-I peptides are intracellular-cleaved peptides, usually 8–11 amino acids in length, which are presented on the cell surface and facilitate CD8+ T cell responses. Despite the appreciation of CD8+ T-cell antitumor immune responses toward improvement in patient outcomes, the MHC-I peptide ligands that facilitate the response are poorly described. Along these same lines, although many therapies have been recognized for their ability to reinvigorate antitumor CD8+ T-cell responses, whether these t...
Published on Feb 7, 2019in Blood 16.56
Tatjana Bilich2
Estimated H-index: 2
(University of Tübingen),
Annika Nelde3
Estimated H-index: 3
(University of Tübingen)
+ 22 AuthorsMarian Christoph Neidert10
Estimated H-index: 10
(UZH: University of Zurich)
Antileukemia immunity plays an important role in disease control and maintenance of tyrosine kinase inhibitor (TKI)-free remission in chronic myeloid leukemia (CML). Thus, antigen-specific immunotherapy holds promise for strengthening immune control in CML but requires the identification of CML-associated targets. In this study, we used a mass spectrometry–based approach to identify naturally presented HLA class I– and class II–restricted peptides in primary CML samples. Comparative HLA ligandom...
Published on Aug 7, 2018in Scientific Data
Heiko Schuster13
Estimated H-index: 13
,
Wenguang Shao2
Estimated H-index: 2
+ 10 AuthorsRobert L. Moritz58
Estimated H-index: 58
Published on Oct 1, 2018
S Braun , Ana Marcu3
Estimated H-index: 3
(University of Tübingen)
+ 9 AuthorsH.-G. Rammensee7
Estimated H-index: 7
(University of Tübingen)
Published on Aug 15, 2018in Cancer Research 8.38
Markus Loeffler77
Estimated H-index: 77
(University of Tübingen),
Daniel J. Kowalewski10
Estimated H-index: 10
(University of Tübingen)
+ 15 AuthorsStefan Beckert17
Estimated H-index: 17
Immune cell infiltrates have proven highly relevant for colorectal carcinoma prognosis, making colorectal cancer a promising candidate for immunotherapy. Because tumors interact with the immune system via HLA-presented peptide ligands, exact knowledge of the peptidome constitution is fundamental for understanding this relationship. Here, we comprehensively describe the naturally presented HLA ligandome of colorectal carcinoma and corresponding nonmalignant colon (NMC) tissue. Mass spectrometry i...
Published on Jun 1, 2018in Proteomics 3.11
Jens Fritsche8
Estimated H-index: 8
,
Barbara Rakitsch1
Estimated H-index: 1
+ 14 AuthorsArun Satelli14
Estimated H-index: 14
Published on Jan 4, 2018in Nucleic Acids Research 11.15
Wenguang Shao2
Estimated H-index: 2
(ETH Zurich),
Patrick G. A. Pedrioli22
Estimated H-index: 22
(ETH Zurich)
+ 43 AuthorsFabio Marino13
Estimated H-index: 13
(UU: Utrecht University)
Mass spectrometry (MS)-based immunopeptidomics investigates the repertoire of peptides presented at the cell surface by major histocompatibility complex (MHC) molecules. The broad clinical relevance of MHC-associated peptides, e.g. in precision medicine, provides a strong rationale for the large-scale generation of immunopeptidomic datasets and recent developments in MS-based peptide analysis technologies now support the generation of the required data. Importantly, the availability of diverse i...
Heiko Schuster13
Estimated H-index: 13
(University of Tübingen),
Janet Kerstin Peper6
Estimated H-index: 6
(University of Tübingen)
+ 21 AuthorsNico Trautwein7
Estimated H-index: 7
(University of Tübingen)
Abstract Immunotherapies, particularly checkpoint inhibitors, have set off a revolution in cancer therapy by releasing the power of the immune system. However, only little is known about the antigens that are essentially presented on cancer cells, capable of exposing them to immune cells. Large-scale HLA ligandome analysis has enabled us to exhaustively characterize the immunopeptidomic landscape of epithelial ovarian cancers (EOCs). Additional comparative profiling with the immunopeptidome of a...
12345